Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

Regeneron gests US FDA approval for Libtayo as an adjuvant treatment of CSCC with a high risk of recurrence after surgery and radiation: Tarrytown, New York Friday, October 10, 20 ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...

Preliminary findings for dopaminergic cell transplantation have reported positive trends towards safety and efficacy for people with Parkinson's disease (PD), according to two studies released at the ...

The trial enrolled patients with unresectable metastatic melanoma who had at least 1 prior line of therapy that had to have the anti–PD-1 therapy backbone. They could or could not have had a BRAF ...

In the article that accompanies this editorial, Wong et al 18 demonstrate significant clinical activity with tolerable toxicities of the second-generation oncolytic virus vusolimogene oderparepvec ...

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to ...

Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the PD-1 inhibitor Libtayo as an adjuvant ...

Work at Aligos Therapeutics Inc. has led to the discovery of new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Angelina Jolie Says She Doesn't Recognize The America She Loves A truck driver not paying attention caused a chain-reaction crash that killed 6 people and injured 41, the NTSB found Scientists Found ...